<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59196">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335359</url>
  </required_header>
  <id_info>
    <org_study_id>Tranex-AAA/34/OSR</org_study_id>
    <nct_id>NCT02335359</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Major Vascular Surgery</brief_title>
  <official_title>Tranexamic Acid in Major Vascular Surgery. A Randomized Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tranexamic acid is effective in reducing
      intraoperative blood loss and necessity for haemotransfusion in patients undergoing open
      abdominal aortic aneurysm repair
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss (milliliters)</measure>
    <time_frame>intraoperative (from skin incision to skin closure)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of packed blood red cells transfused</measure>
    <time_frame>hospital stay (an average of one week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of thromboembolic events (of any nature)</measure>
    <time_frame>28-days and one year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-days and one year after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid diluted in 100 ml of saline solution (loading dose)</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid undiluted (continous infusion)</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 50

          -  Able to give written informed consent

          -  Undergoing open abdominal aortic aneurysm repair

        Exclusion Criteria:

          -  Patients participating in a pharmaceutical clinical trial in the last 3 months

          -  Urgent/emergent surgery

          -  Allergy/intolerance to tranexamic acid

          -  History of seizures

          -  Acute Venous or Arterial Thrombosis

          -  Fibrinolytic conditions due to consumption coagulopathy

          -  Disseminated intravascular coagulation

          -  Haematuria

          -  Visual disturbances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Pasin, MD</last_name>
    <phone>+39 02 2643 6151</phone>
    <email>pasin.laura@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Pasin, MD</last_name>
      <email>pasin.laura@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Landoni, MD</last_name>
      <email>landoni.giovanni@hsr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 4, 2015</lastchanged_date>
  <firstreceived_date>January 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Laura Pasin</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
